NCT05621733 - A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

April 7, 2023

Primary Completion Date

May 9, 2026

Study Completion Date

May 9, 2026

Conditions

Graft-versus-Host Disease

Interventions

OTHER

ruxolitinib

Prospective observational study. There is no treatment allocation. Patients prescribed with ruxolitinib in the commercial setting are eligible to enroll into this study.

Trial Locations (11)

26426

RECRUITING

Novartis Investigative Site, Wŏnju

41944

RECRUITING

Novartis Investigative Site, Taegu

42602

RECRUITING

Novartis Investigative Site, Daegu

48108

RECRUITING

Novartis Investigative Site, Busan

49241

RECRUITING

Novartis Investigative Site, Busan

519763

RECRUITING

Novartis Investigative Site, Jeollanam

06591

RECRUITING

Novartis Investigative Site, Seoul

602-030

RECRUITING

Novartis Investigative Site, Busan

660-702

RECRUITING

Novartis Investigative Site, Jinju

02841

RECRUITING

Novartis Investigative Site, Seoul

05505

RECRUITING

Novartis Investigative Site, Seoul